Recent publications

 
 
 

Future Medicinal Chemistry, 13 Aug 2018

Artificial intelligence in drug discovery

Matthew A Sellwood, Mohamed Ahmed, Marwin HS Segler & Nathan Brown

Future Medicinal Chemistry.png
 

There has been a great deal of hype surrounding the resurgence of Artificial Intelligence and Machine Learning. This commentary was published in Future Medicinal Chemistry as a brief overview of the AI and ML domains, their relevance in different aspects of drug discovery and, importantly, reflecting on managing expectations from different quarters. The key themes covered are molecular design approaches, including our recent paper on do novo design models, predictive modelling, synthesis planning, and closing the feedback loop to learn from our decisions.

Read more

 

british medical journal, 7 june 2018

Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005

Magdalena Zwierzyna, Mark Davies, Aroon D Hingorani, Jackie Hunter

Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov
 

Clinicaltrials.gov is the world’s largest primary registry of clinical studies. For almost two decades now  it has been helping physicians, patients, and regulators identify relevant trials and collect evidence. It also offers a unique opportunity to explore, examine, and monitor the clinical research landscape.  In our recent research paper, we used the clinicaltrials.gov registry data to conduct a comprehensive large-scale analysis of registered clinical trials and investigate trends in their design and transparency. 

Read more  |  BMJ Opinion

 

Progress in Medicinal Chemistry, Volume 57, elsevier, 10 April 2018

Chapter Five - Big Data in Drug Discovery

Nathan Brown, Jean Cambruzzi, Peter J. Cox, Mark Davies, James Dunbar, Dean Plumbley, Matthew A.Sellwood, Aaron Sim, Bryn I. Williams-Jones, Magdalena Zwierzyna, David W.Sheppard

Screen Shot 2018-08-16 at 14.30.19.png
 

Modern scientific discovery is driven by data and learning from those data. This book chapter offers an overview of available data sources of relevance to drug discovery and how these can and do make an impact in our research and predictions to make better informed decisions that more rapidly make changes in our discovery research ethic to progress drugs to the clinic.

Read more

 

 

Nature Chemistry, 4 April 2018

Organic synthesis provides opportunities to transform drug discovery

Ian Churcher et al

Screen Shot 2018-08-16 at 12.59.06.png
 

Ian Churcher, VP Drug Discovery recently published a paper in Nature to highlight how organic synthesis could represent an opportunity for the pharmaceuticals industries to improve drug development. He presents the current challenges that the industry needs overcome and explains how new technologies and industry-academia collaborations are essential to progress.

Read more  |  Blog

 

 

Nature, 28 March 2018

 

Planning chemical syntheses with deep neural networks and symbolic AI

Marwin Segler et al

Screen Shot 2018-08-14 at 23.48.01.png
 

The AI technology developed by Marwin uses deep neural networks to learn from every chemical reaction ever performed (12.4 million of them). Combined with modern tree search algorithms, this allows to plan the synthesis of novel molecules. The technology augments the ability of chemists to make molecules faster, increases the success rate of synthetic chemistry and the speed and efficiency of drug development in general.

Read more

 

OPEN REVIEW, ICLR 2018, 27 March 2018

Exploring deep recurrent models with reinforcement learning for molecule design

Daniel Neil, Marwin Segler, Laura Guasch, Mohamed Ahmed, Dean Plumbley, Matthew Sellwood, Nathan Brown

Screen Shot 2018-08-16 at 13.49.54.png
 

The essence of molecular design is to effectively fulfill a molecular property profile that is desirable as a drug. In this paper we consider a number of different generative models for the design of new molecular structures the satisfy specific multiple objectives that are desirable for a particular drug discovery project. In addition to the evaluation of multiple generative models, we also presented as part of this work a benchmarking dataset to the community with the aim to provide an objective set to evaluate other new de novo molecular design models appropriately

Read More

 

 

ChemMedChem, 20 March 2018

 

Special Issue: Cheminformatics in Drug Discovery

Andreas Bender, Nathan Brown

Screen Shot 2018-08-14 at 23.32.38.png
 

BenevolentAI guest edited a special issue of ChemMedChem in early 2018 with our Head of Cheminformatics, Nathan Brown, in collaboration with Andreas Bender at the University of Cambridge. The special issue consisted of twenty original research papers from leading names in the field and was introduced with a guest editorial written by Nathan and Andreas, introducing the content. The special issue covered a broad range of topics in Cheminformatics from recent work in Machine Learning in Drug Discovery, to large scale data analyses of protein structures and ligand binding.

Read more